By the same authors

From the same journal

Bringing regenerative medicines to the clinic: the future for regulation and reimbursement

Research output: Contribution to journalArticlepeer-review

Standard

Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. / Bubela, Tania; McCabe, Christopher; Archibald, Peter; Atkins, Harold; Bradshaw, Steven; Kefalas, Panos; Mujoomdar, Michelle; Packer, Claire; Piret, James; Raxworthy, Mike; Soares, Marta; Viswanathan, Sowmya.

In: REGENERATIVE MEDICINE, 13.11.2015.

Research output: Contribution to journalArticlepeer-review

Harvard

Bubela, T, McCabe, C, Archibald, P, Atkins, H, Bradshaw, S, Kefalas, P, Mujoomdar, M, Packer, C, Piret, J, Raxworthy, M, Soares, M & Viswanathan, S 2015, 'Bringing regenerative medicines to the clinic: the future for regulation and reimbursement', REGENERATIVE MEDICINE. https://doi.org/10.2217/rme.15.51

APA

Bubela, T., McCabe, C., Archibald, P., Atkins, H., Bradshaw, S., Kefalas, P., Mujoomdar, M., Packer, C., Piret, J., Raxworthy, M., Soares, M., & Viswanathan, S. (2015). Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. REGENERATIVE MEDICINE. https://doi.org/10.2217/rme.15.51

Vancouver

Bubela T, McCabe C, Archibald P, Atkins H, Bradshaw S, Kefalas P et al. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. REGENERATIVE MEDICINE. 2015 Nov 13. https://doi.org/10.2217/rme.15.51

Author

Bubela, Tania ; McCabe, Christopher ; Archibald, Peter ; Atkins, Harold ; Bradshaw, Steven ; Kefalas, Panos ; Mujoomdar, Michelle ; Packer, Claire ; Piret, James ; Raxworthy, Mike ; Soares, Marta ; Viswanathan, Sowmya. / Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. In: REGENERATIVE MEDICINE. 2015.

Bibtex - Download

@article{ae4c5f68728b4d46bcabee34a788b747,
title = "Bringing regenerative medicines to the clinic:: the future for regulation and reimbursement",
abstract = "Significant investments in regenerative medicine necessitate discussion to align evidentiary requirements and decision-making considerations from regulatory, health system payer and developer perspectives. Only with coordinated efforts will the potential of regenerative medicine be realized. We report on discussions from two workshops sponsored by NICE, University of Alberta, Cell Therapy Catapult and Centre for Commercialization of Regenerative Medicine. We discuss methods to support the assessment of value for regenerative medicine products and services and the synergies that exist between market authorization and reimbursement regulations and practices. We discuss the convergence in novel adaptive licensing practices that may promote the development and adoption of novel therapeutics that meet the needs of healthcare payers.",
author = "Tania Bubela and Christopher McCabe and Peter Archibald and Harold Atkins and Steven Bradshaw and Panos Kefalas and Michelle Mujoomdar and Claire Packer and James Piret and Mike Raxworthy and Marta Soares and Sowmya Viswanathan",
year = "2015",
month = nov,
day = "13",
doi = "10.2217/rme.15.51",
language = "English",
journal = "REGENERATIVE MEDICINE",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Bringing regenerative medicines to the clinic:

T2 - the future for regulation and reimbursement

AU - Bubela, Tania

AU - McCabe, Christopher

AU - Archibald, Peter

AU - Atkins, Harold

AU - Bradshaw, Steven

AU - Kefalas, Panos

AU - Mujoomdar, Michelle

AU - Packer, Claire

AU - Piret, James

AU - Raxworthy, Mike

AU - Soares, Marta

AU - Viswanathan, Sowmya

PY - 2015/11/13

Y1 - 2015/11/13

N2 - Significant investments in regenerative medicine necessitate discussion to align evidentiary requirements and decision-making considerations from regulatory, health system payer and developer perspectives. Only with coordinated efforts will the potential of regenerative medicine be realized. We report on discussions from two workshops sponsored by NICE, University of Alberta, Cell Therapy Catapult and Centre for Commercialization of Regenerative Medicine. We discuss methods to support the assessment of value for regenerative medicine products and services and the synergies that exist between market authorization and reimbursement regulations and practices. We discuss the convergence in novel adaptive licensing practices that may promote the development and adoption of novel therapeutics that meet the needs of healthcare payers.

AB - Significant investments in regenerative medicine necessitate discussion to align evidentiary requirements and decision-making considerations from regulatory, health system payer and developer perspectives. Only with coordinated efforts will the potential of regenerative medicine be realized. We report on discussions from two workshops sponsored by NICE, University of Alberta, Cell Therapy Catapult and Centre for Commercialization of Regenerative Medicine. We discuss methods to support the assessment of value for regenerative medicine products and services and the synergies that exist between market authorization and reimbursement regulations and practices. We discuss the convergence in novel adaptive licensing practices that may promote the development and adoption of novel therapeutics that meet the needs of healthcare payers.

U2 - 10.2217/rme.15.51

DO - 10.2217/rme.15.51

M3 - Article

C2 - 26565607

JO - REGENERATIVE MEDICINE

JF - REGENERATIVE MEDICINE

SN - 1746-0751

ER -